University Purpose Approximately 68000 cases of all types of keratoplasty procedures were performed in the US in 2012. Immunologic graft rejection is a main cause for corneal graft failure. Steroids are the most commonly used immunosuppressants for management and treatment of corneal graft rejection. However, eye drops undergo rapid ocular clearance, thus frequent dosing of eye drops is required for corneal rejection management. Long-term frequent use of topical corticosteroids can cause poor patient compliance and increased steroid-related side effects. Here we developed corticosteroids-loaded nanoparticles to prevent the cornea allograft rejection in a rat model. Methods Nanoparticles (NP) were prepared by solvent diffusion method, and water-soluble dexamethasone sodium phosphate (DSP) was co-encapsulated with zinc into poly(lactic-co-glycolic acid) nanoparticles (DSP-NP). The penetrating keratoplasty (PKP) was carried out by transplanting the central corneal button of Fisher donor rat to the corneal bed of recipient Lewis rat. After PKP, animals were randomly divided into 4 groups (n=5) undertaking 50µL subconjunctival (SC) administration of: saline, placebo NP, free DSP (2mgDSP/ml) and DSP-NP (2mgDSP/ml). All groups were undertaken same treatment once every week until the failure of grafts or the end of the study (PO 9weeks). Clinical observations (cornea opacity, edema, neovascularization) have been performed to examine the corneal graft rejection, and intraocular pressure (IOP) was monitored. Results Nanoparticles exhibit size ~200nm, high drug loading of 12wt% and controlled drug release profile (Fig1). We show that these DSP-NPs provided sustained ocular drug levels after SC administration to rat eyes, and prevented corneal allograft rejection in rats over the entire 9week study (Fig1). In comparison, corneal rejection in control treatment groups of either placebo particles, saline or free DSP solution occurred within less than 4weeks accompanied by severe corneal edema, neovascularization and opacity. Nanoparticles did not induce increased IOP and also showed no ocular toxicity. Conclusion Nanoparticles provide sustained release of corticosteroids and effectively prevents the corneal allograft rejection in rats. This nanoparticle treatment strategy reduces administration frequency and may improve patient compliance. Furthermore, nanoparticles are made of GRAS materials, which should facilitate translation to human use.
